To present a survey of the features of published slit lamp-based scoring systems and their applicability in the context of modern ocular toxicology and drug development.
Methods:
References describing original or modified slit lamp-based scoring systems for human or veterinary clinical patients or in investigative or toxicologic research were collected following a comprehensive literature review using textbooks and online publication searches. Each system's indications and features were compiled to facilitate comparison.
Results:
Literature review identified 138 original or modified scoring systems. Most (48%) were published for evaluation of the ocular surface, 34% for the general anterior segment, and 18% for the lens. Most systems were described for assessment of human patients (50%) and small albino laboratory species such as rabbits (19%), rats (12%), and mice (8%). Systems described for pigmented laboratory species and for larger species such as dogs, cats, pigs, and nonhuman primates (NHPs) were comparatively underrepresented. No systems described a lens scoring scheme specific to the dog, cat, pig, or NHP. Scoring schemes for aqueous and vitreous cells were infrequently described for laboratory species.
Conclusions:
Many slit lamp-based scoring systems have been published, but the features of each differ and complicate translation of findings between different species. Use and interpretation of any scoring system in toxicology and drug development must be done with awareness of the limitations of the system being used.
Get full access to this article
View all access options for this article.
References
1.
GellrichM.M.History of the slit lamp. The Slit Lamp. Berlin Heidelberg: Springer; 2014; p. 189–210.
2.
ÜberreiterO.Die Mikroskopie am lebenden Tierauge. Wien. tierärztl. Mschr., 43:77, 1956.
3.
ÜberreiterO.Examination of the eye and eye operations in animals. Adv. Vet. Sci., 5:1–80, 1959.
4.
MartinC.L.Slit lamp examination of the normal canine anterior ocular segment. 3. Discussion and summary. J. Small Anim. Pract., 10:163–169, 1969.
5.
MartinC.L.Slit lamp examination of the normal canine anterior ocular segment. II. Description. J. Small Anim. Pract., 10:151–162, 1969.
6.
MartinC.L.Slit lamp examination of the normal canine anterior ocular segment. I. Introduction and technique. J. Small Anim. Pract., 10:143–149, 1969.
7.
FeatherstoneH.J., and HeinrichC.L.Ophthalmic examination and diagnostics. In: GelattK.N., GilgerB.C., and KernT.J., eds. Veterinary Ophthalmology, 5th ed. Ames, Iowa: Wiley-Blackwell; 2013; p. 568–572.
8.
MungerR.J.Veterinary ophthalmology in laboratory animal studies. Vet. Ophthalmol., 5:167–175, 2002.
9.
WilkieD.A. The Ophthalmic Examination as It Pertains to General Ocular Toxicology: basic and Advanced Techniques and Species-Associated Findings. In: GilgerB.C., ed. Ocular Pharmacology and Toxicology. New York: Springer; 2014; p. 143–203.
10.
JabsD.A., NussenblattR.B., and RosenbaumJ.T.Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am. J. Ophthalmol., 140:509–516, 2005.
11.
DraizeJ.H., WoodardG., and CalveryH.O.Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharmacol. Exp. Ther., 82:377–390, 1944.
12.
McDonaldT.O., and ShadduckJ.A.Eye irritation. In: MarzulliF.N., MaibachH.I., eds. Advances in Modern Toxicology, Volume IV: Dermatotoxicology and Pharmacology. Washington, D.C.: Hemisphere Publishing Corp; 1977; p. 139–191.
13.
HackettR.B., and McDonaldT.O.Assessing ocular irritation. In: MarzulliF.N., MaibachH.I., eds. Dermatotoxicology, 5th Edition. Washington, DC: Hemisphere Publishing Corp.; 1996; p. 557–567.
SingerM.Oxford Textbook of Critical Care. New York, NY: Oxford University Press; 2016.
16.
BouchD.C., and ThompsonJ.P.Severity scoring systems in the critically ill. Contin. Educ. Anaesth. Critic. Care Pain., 8:181–185, 2008.
17.
BarbiniP., CeveniniG., FuriniS., and BarbiniE.A naive approach for deriving scoring systems to support clinical decision making. J. Eval. Clin. Pract., 20:1–6, 2014.
18.
ThomasyS.M., EatonJ.S., TimberlakeM.J., et al.Species differences in the geometry of the anterior segment differentially affect anterior chamber cell scoring systems in laboratory animals. J. Ocul. Pharmacol. Ther., 32:28–37, 2016.
19.
GilgerB.C., AbarcaE., and SalmonJ.H.Selection of appropriate animal models in ocular research: ocular anatomy and physiology of common animal models. In: GilgerB.C., ed. Ocular Pharmacology and Toxicology. New York: Springer; 2014; p. 7–32.
20.
StewartW.C., MagrathG.N., DemosC.M., et al.Predictive value of the efficacy of glaucoma medications in animal models: preclinical to regulatory studies. Br. J. Ophthalmol., 95:1355–1360, 2011.
21.
SasakiH., YamamuraK., NishidaK., et al.Delivery of drugs to the eye by topical application. Prog. Retin. Eye Res., 15:583–620, 1996.
22.
SalminenL., UrttiA., and PeriviitaL.Effect of ocular pigmentation on pilocarpine pharmacology in the rabbit eye. I. Drag distribution and metabolism. Int. J. Pharm., 18:17–24, 1984.
23.
UrttiA., SalminenL., KujariH., et al.Effect of ocular pigmentation on pilocarpine pharmacology in the rabbit eye. II. Drug response. Int. J. Pharm., 19:53–61, 1984.
24.
MungerR.J., and CollinsM.Assessment of ocular toxicity potential: basic theory and techniques. In: WeirA.B., CollinsM., eds. Assessing Ocular Toxicology in Laboratory Animals. New York, NY: Humana Press; 2013; p. 23–52.
25.
BitoL.Z.Species differences in the responses of the eye to irritation and trauma: a hypothesis of divergence in ocular defense mechanisms, and the choice of experimental animals for eye research. Exp. Eye Res., 39:807–829, 1984.
26.
NussenblattR.B., PalestineA.G., ChanC.-C., et al.Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmol. 92:467–471, 1985.
27.
BarabinoS., and DanaM.R.Animal models of dry eye: a critical assessment of opportunities and limitations. Invest. Ophthalmol. Vis. Sci., 45:1641–1646, 2004.
28.
SchraderS., MircheffA., and GeerlingG.Animal models of dry eye. In: GeerlingG., and BrewittH., eds., Surgery for the Dry Eye: scientific Evidence and Guidelines for the Clinical Management of Dry Eye Associated Ocular Surface Disease. Vol. 41. Karger Publishers; 2008; p. 298–312.
29.
LeonardB.C., Yañez-SotoB., RaghunathanV.K., et al.Species variation and spatial differences in mucin expression from corneal epithelial cells. Exp. Eye Res., 152:43–48, 2016.
30.
HanashiroR.K., FujinoY., SamuraM., et al.Synthetic lipid A-induced uveitis and endotoxin-induced uveitis—a comparative study. Jpn. J. Ophthalmol., 41:355–361, 1997.
31.
KostO.A., BeznosO.V., DavydovaN.G., et al.Superoxide dismutase 1 nanozyme for treatment of eye inflammation. Oxid. Med. Cell Longev. 2015.
32.
ForresterJ., WorgulB., and MerriamG.Endotoxin-induced uveitis in the rat. Graefe's Arch. Clin. Exper. Ophthalmol., 213:221–233, 1980.
33.
ZaidiA.A., YingG.-S., DanielE., et al.Hypopyon in patients with uveitis. Ophthalmol. 117:366–372, 2010.
34.
McCormickC., CaballeroA., TangA., et al.Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis. Curr. Med. Res. Opin., 24:1569–1575, 2008.
35.
FriedenwaldJ., HughesW., and HerrmannH.Acid-base tolerance of the cornea. Arch. Ophthalmol., 31:279–283, 1944.
36.
JohnsonM.K., HobdenJ.A., HagenahM., et al.The role of pneumolysin in ocular infections with Streptococcus pneumoniae. Curr. Eye Res., 9:1107–1114, 1990.
37.
CousinsS.W., TrattlerW.B., and StreileinJ.W.Immune privilege and suppression of immunogenic inflammation in the anterior chamber of the eye. Curr. Eye Res., 10:287–297, 1991.
38.
BerdyG.J., AbelsonM.B., GeorgeM.A., et al.Allergic conjunctivitis: a survey of new antihistamines. J. Ocul. Pharmacol., 7:313–324, 1991.
39.
BellotJ.L., PalmeroM., Garcia-CabanesC., et al.Additive effect of nitric oxide and prostaglandin-E2 synthesis inhibitors in endotoxin-induced uveitis in the rabbit. Inflamm. Res., 45:203–208, 1996.
40.
PapaV., MilazzoG., SantoconoM., et al.Naproxen ophthalmic solution to manage inflammation after phacoemulsification. J. Cataract. Refract. Surg., 28:321–327, 2002.
41.
LedbetterE.C., MunJ.J., KowbelD., et al.Pathogenic phenotype and genotype of Pseudomonas aeruginosa isolates from spontaneous canine ocular infections. Invest. Ophthalmol. Vis. Sci., 50:729–736, 2009.
42.
MaggsD.J., NasisseM.P., MarrionR.M., et al.Effects of intracameral administration of alpha-chymotrypsin on intracapsular lens extraction and postoperative outcome in clinically normal dogs. Am. J. Vet. Res., 71:1475–1483, 2010.
43.
KulkarniP.S., BhattacherjeeP., EakinsK.E., et al.Anti-inflammatory effects of betamethasone phosphate, dexamethasone phosphate and indomethacin on rabbit ocular inflammation induced by bovine serum albumin. Curr. Eye Res., 1:43–47, 1981.
44.
ZhengX., YamaguchiM., GotoT., et al.Experimental corneal endotheliitis in rabbit. Invest. Ophthalmol. Vis. Sci., 41:377–385, 2000.
45.
Del SoleM.J., SandeP.H., FelipeA.E., et al.Characterization of uveitis induced by use of a single intravitreal injection of bacterial lipopolysaccharide in cats. Am. J. Vet. Res., 69:1487–1495, 2008.
46.
RozeM., ThomasE., and DavotJ.L.Tolfenamic acid in the control of ocular inflammation in the dog: pharmacokinetics and clinical results obtained in an experimental model. J. Small Anim. Pract., 37:371–375, 1996.
47.
RochaG., BainesM.G., DeschecnesJ., et al.Transforming growth factor-beta levels in aqueous humor during experimentally induced uveitis. Ocul. Immunol. Inflamm., 1:343–354, 1993.
48.
DunneJ.A., and TraversJ.P.Double-blind clinical trial of topical steroids in anterior uveitis. Br. J. Ophthalmol., 63:762–767, 1979.
49.
GilgerB.C., AbarcaE.M., SalmonJ.H., et al.Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles. Invest. Ophthalmol. Vis. Sci., 54:2483–2492, 2013.
50.
BaldwinH.A., McDonaldT.O., and BeasleyC.H.Slit-lamp examination of experimental animal eyes. II. Grading scales and photographic evaluation of induced pathological conditions. J. Soc. Cosmet. Chem., 24:181–195, 1973.
51.
AltmannS., EmanuelA., ToomeyM., et al.A quantitative rabbit model of vaccinia keratitis. Invest. Ophthalmol. Vis. Sci., 51:4531–4540, 2010.
52.
ChambersW.A., GreenS., GuptaK.C., et al.Scoring for eye irritation tests. Food Chem. Toxicol., 31:111–115, 1993.
53.
KrzystolikM.G., AfshariM.A., AdamisA.P., et al.Prevention of experimental choroidal neovascularization with intravitreal antiΓÇôvascular endothelial growth factor antibody fragment. Arch. Ophthalmol., 120:338–346, 2002.
54.
RussoP., PapaV., RussoS., et al.Topical nonsteroidal anti-inflammatory drugs in uncomplicated cataract surgery: effect of sodium naproxen. Eur. J. Ophthalmol., 15:598–606, 2005.
55.
KawashimaH., and MochizukiM.Effects of a new immunosuppressive agent, FK 506, on the efferent limb of the immune responses. Exp. Eye Res., 51:565–572, 1990.
56.
HoekzemaR., MurrayP.I., van HarenM.A., et al.Analysis of interleukin-6 in endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci., 32:88–95, 1991.
57.
OkadaA.A., KeinoH., FukaiT., et al.Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul. Immunol. Inflamm., 6:215–226, 1998.
58.
ZhengC., LeiC., ChenZ., et al.Topical administration of diminazene aceturate decreases inflammation in endotoxin-induced uveitis. Mol. Vis., 21:403–411, 2015.
59.
KaburakiT., NambaK., SonodaK.H., et al.Behcet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn. J. Ophthalmol., 58:120–130, 2014.
60.
AltinsoyA., DilekozE., KulO., et al.A cannabinoid ligand, anandamide, exacerbates endotoxin-induced uveitis in rabbits. J. Ocul. Pharmacol. Ther., 27:545–552, 2011.
61.
Ruiz-MorenoJ.M., ThillayeB., and de KozakY.Retino-choroidal changes in endotoxin-induced uveitis in the rat. Ophthalmic. Res., 24:162–168, 1992.
62.
BucoloC., CuzzocreaS., MazzonE., et al.Effects of cloricromene, a coumarin derivative, on endotoxin-induced uveitis in Lewis rats. Invest. Ophthalmol. Vis. Sci., 44:1178–1184, 2003.
63.
MathewsJ.D., CrawfordB.A., BignellJ.L., et al.Azathioprine in active chronic iridocyclitis. A double-blind controlled trial. Br. J. Ophthalmol., 53:327–330, 1969.
64.
SmithJ.R., HartP.H., ParishC.R., et al.Experimental melanin-induced uveitis in the Fischer 344 rat is inhibited by anti-CD4 monoclonal antibody, but not by mannose-6-phosphate. Clin. Exp. Immunol., 115:64–71, 1999.
65.
Tugal-TutkunI., CingüK., KirN., et al.Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet uveitis. Graefe's Arch. Clin. Exp. Ophthalmol., 246:1169–1177, 2008.
66.
HoganM.J., KimuraS.J., and ThygesonP.Signs and symptoms of uveitis. I. Anterior uveitis. Am. J. Ophthalmol. 47(5 Pt 2), 155–170, 1959.
67.
MartinP.L., MillerP.E., MataM., et al.Ocular inflammation in cynomolgus macaques following intravenous administration of a human monoclonal antibody. Int. J. Toxicol., 28:5–16, 2009.
68.
BrownD.M., KaiserP.K., MichelsM., et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med., 355:1432–1444, 2006.
69.
Hafezi-MoghadamA., NodaK., AlmulkiL., et al.VLA-4 blockade suppresses endotoxin-induced uveitis: in vivo evidence for functional integrin up-regulation. FASEB J. 21:464–474, 2007.
70.
BenEzraD., ForresterJ.V., NussenblattR.B., et al.Uveitis Scoring System. Berlin Heidelberg: Springer; 1991; p. 1–2.
71.
KimuraS.J., ThygesonP., and HoganM.J.Signs and symptoms of uveitis. II. Classification of the posterior manifestations of uveitis. Am. J. Ophthalmol. 47, 1959.
72.
CarpenterC.P., SmythH.F.Jr. Chemical burns of the rabbit cornea. Am. J. Ophthalmol., 29:1363–1372, 1946.
73.
BarnettR.A., and AronsonS.B.A biomicroscopic method for quantitation of ocular and adnexal toxicity. Fundam. Appl. Toxicol., 3:187–191, 1983.
74.
The Age-Related Eye Disease Study (AREDS). System for classifying cataracts from photographs: AREDS Report No 4. Am. J. Ophthalmol., 131:167–175, 2001.
75.
SparrowJ.M., BronA.J., BrownN.A.P., et al.The Oxford clinical cataract classification and grading system. Int. Ophthalmol., 9:207–225, 1986.
ChylackL.T., LeskeM.C., McCarthyD., et al.Lens opacities classification system II (LOCS II). Arch. Ophthalmol., 107:991–997, 1989.
78.
ChylackL.T., WolfeJ.K., SingerD.M., et al.The lens opacities classification system III. Arch. Ophthalmol., 111:831–836, 1993.
79.
WallT., and BjerkasE.A simplified method of scoring cataracts in fish. Bull. Eur. Assoc. Fish Pathol., 19:162–165, 1999.
80.
KwonY.H., KimC.S., ZimmermanM.B., et al.Rate of visual field loss and long-term visual outcome in primary open-angle glaucoma. Am. J. Ophthalmol., 132:47–56, 2001.
81.
RobertsonL.J., MortonJ.D., YamaguchiM., et al.Calpain may contribute to hereditary cataract formation in sheep. Invest. Ophthalmol. Vis. Sci., 46:4634–4640, 2005.
82.
LeeH.Y., MortonJ.D., RobertsonL.J., et al.Evaluation of a novel calpain inhibitor as a treatment for cataract. Clin. Exp. Ophthalmol., 36:852–860, 2008.
83.
LassenN., BatemanJ.B., EsteyT., et al.Multiple and additive functions of ALDH3A1 and ALDH1A1: cataract phenotype and ocular oxidative damage in Aldh3a1(-/-)/Aldh1a1(-/-) knock-out mice. J. Biol. Chem., 282:25668–25676, 2007.
ChenB.Y., LinD.P., SuK.C., et al.Dietary zerumbone prevents against ultraviolet B-induced cataractogenesis in the mouse. Mol. Vis., 17:723–730, 2011.
86.
XuG.T., ZiglerJ.S.Jr., and LouM.F.The possible mechanism of naphthalene cataract in rat and its prevention by an aldose reductase inhibitor (ALO1576). Exp. Eye Res., 54:63–72, 1992.
87.
MortonJ.D., LeeH.Y., McDermottJ.D., et al.A macrocyclic calpain inhibitor slows the development of inherited cortical cataracts in a sheep model. Invest Ophthalmol. Vis. Sci., 54:389–395, 2013.
88.
DynlachtJ.R., TyreeC., ValluriS., et al.Effect of estrogen on radiation-induced cataractogenesis. Radiat. Res., 165:9–15, 2006.
89.
GwonA.E., JonesR.L., GruberL.J., et al.Lens regeneration in juvenile and adult rabbits measured by image analysis. Invest. Ophthalmol. Vis. Sci., 33:2279–2283, 1992.
90.
JoseJ.G., and AinsworthE.J.Cataract production in mice by heavy charged argon, neon, and carbon particles. Radiat. Res., 94:513–528, 1983.
91.
WorgulB., KundiyevY., SergiyenkoN., et al.Cataracts among Chernobyl clean-up workers: implications regarding permissible eye exposures. Radiat. Res., 167:233–243, 2007.
92.
KleinB.E., KleinR., LintonK.L., et al.Assessment of cataracts from photographs in the Beaver Dam Eye Study. Ophthalmol. 97:1428–1433, 1990.
93.
MerriamG.R.Jr., and FochtE.F.A clinical and experimental study of the effect of single and divided doses of radiation on cataract production. Trans. Am. Ophthalmol. Soc., 60:35–52, 1962.
94.
ThyleforsB., ChylackL.T.Jr., KonyamaK., et al.A simplified cataract grading system The WHO Cataract Grading Group. Ophthalmic Epidemiol. 9:83–95, 2002.
95.
BronA., and BrownN.Classification, grading and prevention of cataract. J. Int. Biomed. Inform. Data., 4:21–47, 1983.
96.
ChylackL.T.Classification of human cataractous change by the American Cooperative Cataract Research Group method. In: ciba Foundation Symposium Vol. 106- Human Cataract Formation. London, United Kingdom: Wiley Online Library; 1984; p. 3–24.
97.
AdamsonsI., TaylorK., EngerC., et al.A new method for documenting lens opacities. Am. J. Ophthalmol., 111:65–70, 1991.
98.
MunozB., WestS., WangF., et al.Measuring cataract progression for longitudinal studies. Invest. Ophthalmol. Vis. Sci., 32:1243–1243, 1991.
99.
FrankG.M., DivitoS.J., MakerD.M., et al.A novel p40-independent function of IL-12p35 is required for progression and maintenance of herpes stromal keratitis. Invest. Ophthalmol. Vis. Sci., 51:3591–3598, 2010.
100.
LinC.P., and BoehnkeM.Effect of fortified antibiotic solutions on corneal epithelial wound healing. Cornea. 19:204–206, 2000.
101.
McCluskeyP., and WakefieldD.Prediction of response to treatment in patients with scleritis using a standardised scoring system. Aust. N. Z. J. Ophthalmol., 19:211–215, 1991.
102.
AhmedR.A., and AzzamS.A.Management of acquired punctal stenosis in trachomatous patients using single versus double silicone tube insertion (a pilot study). Kasr. Al Ainy. Med. J., 22:1, 2016.
103.
BabinM.C., RickettsK.M., GazawayM.Y., et al.A combination drug treatment against ocular sulfur mustard injury. J. Toxicol. Cutaneous. Ocul. Toxicol., 23:65–75, 2005.
104.
KamiyaK., NakanishiM., IshiiR., et al.Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. Eye (Lond). 26:1363–1368, 2012.
105.
LabcharoenwongsP., JirapongsananurukO., VisitsunthornN., et al.A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac. J. Allergy Immunol., 30:177–184, 2012.
106.
MatsumotoY., SatoE.A., IbrahimO.M., et al.The application of in vivo laser confocal microscopy to the diagnosis and evaluation of meibomian gland dysfunction. Mol. Vis., 14:1263–1271, 2008.
107.
YoeruekE., ZiemssenF., Henke-FahleS., et al.Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 86:322–328, 2008.
108.
OhJ.Y., KimM.K., ChoiH.J., et al.Investigating the relationship between serum interleukin-17 levels and systemic immune-mediated disease in patients with dry eye syndrome. Korean J. Ophthalmol., 25:73–76, 2011.
109.
AragonaP., AguennouzM., RaniaL., et al.Matrix metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease. Ophthalmol. 122:62–71, 2015.
110.
De PaivaC.S., and PflugfelderS.C.Corneal epitheliopathy of dry eye induces hyperesthesia to mechanical air jet stimulation. Am. J. Ophthalmol., 137:109–115, 2004.
111.
DenS., SotozonoC., KinoshitaS., et al.Efficacy of early systemic betamethasone or cyclosporin A after corneal alkali injury via inflammatory cytokine reduction. Acta Ophthalmol. Scand., 82:195–199, 2004.
PrabhasawatP., TesavibulN., and KasetsuwanN.Performance profile of sodium hyaluronate in patients with lipid tear deficiency: randomised, double-blind, controlled, exploratory study. Br. J. Ophthalmol., 91:47–50, 2007.
114.
RodriguezJ.D., JohnstonP.R., OuslerG.W., et al.Automated grading system for evaluation of ocular redness associated with dry eye. Clin. Ophthalmol., 7:1197–1204, 2013.
115.
RodriguezJ.D., LaneK.J., OuslerG.W., et al.Automated grading system for evaluation of superficial punctate keratitis associated with dry eye. Invest. Ophthalmol. Vis. Sci., 56:2340–2347, 2015.
116.
TerryR.L., SchniderC.M., HoldenB.A., et al.CCLRU standards for success of daily and extended wear contact lenses. Optom. Vis. Sci., 70:234–243, 1993.
117.
WuT.G., WilhelmusK.R., and MitchellB.M.Experimental keratomycosis in a mouse model. Invest. Ophthalmol. Vis. Sci., 44:210–216, 2003.
118.
EfronN.Clinical application of grading scales for contact lens complications. Optician. 213:26–34, 1997.
119.
AbelsonM.B., ChambersW.A., and SmithL.M.Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch. Ophthalmol., 108:84–88, 1990.
120.
Asano-KatoN., FukagawaK., TsubotaK., et al.Quantitative evaluation of atopic blepharitis by scoring of eyelid conditions and measuring the water content of the skin and evaporation from the eyelid surface. Cornea. 20:255–259, 2001.
121.
BoniniS., BoniniS., LambiaseA., et al.Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmol. 107:1157–1163, 2000.
122.
BronA.J., BenjaminL., and SnibsonG.R.Meibomian gland disease. Classification and grading of lid changes. Eye (Lond)., 5:395–411, 1991.
123.
BronA.J., EvansV.E., and SmithJ.A.Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 22:640–650, 2003.
124.
FengaC., AragonaP., CacciolaA., et al.Meibomian gland dysfunction and ocular discomfort in video display terminal workers. Eye (Lond). 22:91–95, 2008.
125.
JainR., MurthyS.I., BasuS., et al.Anatomic and visual outcomes of descemetopexy in post-cataract surgery descemet's membrane detachment. Ophthalmol. 120:1366–1372, 2013.
126.
LempA.Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. Eye Contact Lens. 21:221–232, 1995.
127.
WhitcherJ.P., ShiboskiC.H., ShiboskiS.C., et al.A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren's Syndrome International Registry. Am. J. Ophthalmol., 149:405–415, 2010.
128.
KorbD.R., BaronD.F., HermanJ.P., et al.Tear film lipid layer thickness as a function of blinking. Cornea. 13:354–359, 1994.
129.
FoulksG.N., and BronA.J.Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul. Surf., 1:107–126, 2003.
130.
SenH.N., SangaveA.A., GoldsteinD.A., et al.A standardized grading system for scleritis. Ophthalmol. 118:768–771, 2011.
131.
HikitaN., LopezJ.S., ChanC.-C., et al.Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest. Ophthalmol. Vis. Sci., 38:901–909, 1997.
132.
van BijsterveldO.P.Diagnostic tests in the Sicca syndrome. Arch. Ophthalmol., 82:10–14, 1969.
133.
BenEzraD.Blepharitis and Conjunctivitis: guidelines for Diagnosis and Treatment: Barcelona, Spain: Editorial Glosa, SL; 2006.
134.
ShojiJ., InadaN., and SawaM.Evaluation of novel scoring system named 5–5-5 exacerbation grading scale for allergic conjunctivitis disease. Allergol. Int., 58:591–597, 2009.
135.
CharooN.A., KohliK., and AliA.Preparation of in situ-forming ophthalmic gels of ciprofloxacin hydrochloride for the treatment of bacterial conjunctivitis: in vitro and in vivo studies. J. Pharm. Sci., 92:407–413, 2003.
136.
DavisK., and TownsendW.Tear-film osmolarity in normal cats and cats with conjunctivitis. Vet. Ophthalmol., 14Suppl 1:54–59, 2011.
137.
FilipecM., PhanT.M., ZhaoT.Z., et al.Topical cyclosporine A and corneal wound healing. Cornea. 11:546–552, 1992.
138.
GahlW.A., KuehlE.M., IwataF., et al.Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol. Genet. Metab., 71:100–120, 2000.
139.
GrauD.R., VisalliR.J., and BrandtC.R.Herpes simplex virus stromal keratitis is not titer-dependent and does not correlate with neurovirulence. Invest. Ophthalmol. Vis. Sci., 30:2474–2480, 1989.
140.
HollandE.J., ChanC.C., WetzigR.P., et al.Clinical and immunohistologic studies of corneal rejection in the rat penetrating keratoplasty model. Cornea. 10:374–380, 1991.
141.
JabsD.A., WingardJ., GreenW.R., et al.The eye in bone marrow transplantation. III. Conjunctival graft-vs-host disease. Arch. Ophthalmol., 107:1343–1348, 1989.
142.
LedbetterE.C., KimS.G., DuboviE.J., et al.Experimental reactivation of latent canine herpesvirus-1 and induction of recurrent ocular disease in adult dogs. Vet. Microbiol., 138:98–105, 2009.
143.
LuchsJ.Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther. 25:858–870, 2008.
144.
MaggsD.J., ChangE., NasisseM.P., et al.Persistence of herpes simplex virus type 1 DNA in chronic conjunctival and eyelid lesions of mice. J. Virol., 72:9166–9172, 1998.
145.
PanZ., ChenY., ZhangW., et al.Rat corneal allograft survival prolonged by the superantigen staphylococcal enterotoxin B. Invest. Ophthalmol. Vis. Sci., 44:3346–3351, 2003.
146.
RobinsonM.R., LeeS.S., RubinB.I., et al.Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant. 33:1031–1035, 2004.
147.
ThompsonP., XuD., BrunetteI., et al.Combined effect of rapamycin and cyclosporine in the prevention of rat corneal allograft rejection. Transplant Proc. 30:1033–1035, 1998.
148.
XinM., WangT., ShiW., et al.Experimental efficacy of mycophenolate mofetil implant on high-risk corneal allograft rejection and its biocompatibility in the anterior chamber of rabbits. J. Ocul. Pharmacol. Ther., 28:609–617, 2012.
149.
Baradaran-RafiiA., EbrahimiM., KanaviM.R., et al.Midterm outcomes of autologous cultivated limbal stem cell transplantation with or without penetrating keratoplasty. Cornea. 29:502–509, 2010.
de AlmeidaD.E., RoverattiC., BritoF.L., et al.Conjunctival effects of canine distemper virus-induced keratoconjunctivitis sicca. Vet. Ophthalmol., 12:211–215, 2009.
152.
ErhamamciS., KaralezliA., YilmazS., et al.The clinical value and histopathological correlation of lacrimal scintigraphy in patients with primary Sjogren's syndrome. Nucl. Med. Commun., 33:689–694, 2012.
153.
MooreJ.E., McMullenT.C., CampbellI.L., et al.The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy. Invest. Ophthalmol. Vis. Sci., 43:2905–2915, 2002.
154.
OzturkF., YavasG.F., KusbeciT., et al.Efficacy of topical caspofungin in experimental fusarium keratitis. Cornea. 26:726–728, 2007.
155.
SchreiberW., OlbrischA., VorwerkC.K., et al.Combined topical fluconazole and corticosteroid treatment for experimental Candida albicans keratomycosis. Invest. Ophthalmol. Vis. Sci., 44:2634–2643, 2003.
156.
SonodaY., and StreileinJ.W.Orthotopic corneal transplantation in mice—evidence that the immunogenetic rules of rejection do not apply. Transplantation. 54:694–704, 1992.
157.
WilliamsD., MiddletonS., FattahianH., et al.Comparison of hyaluronic acid-containing topical eye drops with carbomer-based topical ocular gel as a tear replacement in canine keratoconjunctivitis sicca: a prospective study in twenty five dogs. Vet. Res. Forum., 3:229–232, 2012.
158.
YamaguchiM., KutsunaM., UnoT., et al.Marx line: fluorescein staining line on the inner lid as indicator of meibomian gland function. Am. J. Ophthalmol., 141:669–675, 2006.
159.
CravenE.R., LiuC.C., BatoosinghA., et al.A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost. Clin. Ophthalmol., 4:1433–1440, 2010.
160.
MiyataK., AmanoS., SawaM., et al.A novel grading method for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability. Arch. Ophthalmol., 121:1537–1539, 2003.
161.
EhrenbergM., ZolotariovE., LoebE., et al.Combining sodium hyaluronate and polyvinylpyrrolidone therapies for the rabbit Cornea: a new approach to relief of the human dry eye syndrome. Curr. Eye Res., 40:913–922, 2015.
162.
SotozonoC., AngL.P., KoizumiN., et al.New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. Ophthalmol. 114:1294–1302, 2007.
163.
SotozonoC., InatomiT., NakamuraT., et al.Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory activity. Acta. Ophthalmol., 92:e447–453, 2014.
164.
LempM.A., and FoulksG.N.The definition and classification of dry eye disease. Ocul. Surf., 5:75–92, 2007.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
